NCT02224599 - Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

August 30, 2018

Study Completion Date

August 30, 2018

Conditions

Progressive Solid MalignanciesRefractory Solid MalignanciesCancer

Interventions

BIOLOGICAL

TAPA-pulsed DC vaccine

Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.

DRUG

Cyclophosphamide Pill

Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.

DRUG

Imiquimod Topical Cream

Topical Imiquimod Cream will be applied after vaccination.

Trial Locations (1)

78240

San Antonio